Company intelligence / Profile preview

Ulmus Investment

Ownership: Private
Development stage: Other

Overview

Ulmus Investment is a South Korean venture capital and private equity firm specializing in early to growth-stage investments across technology sectors including biotechnology and healthcare. It has invested in several innovative biotech firms developing monoclonal antibodies and other advanced therapeutics for ophthalmology and oncology indications. The firm does not develop drugs itself but provides capital to companies at various stages of development.

Therapeutic areas: OncologyRare DiseasesOphthalmologyHematology
Modalities: Monoclonal antibodyAntibody-drug conjugateCell therapySmall molecule
Industry: Investors

Partnerships

Industrial Bank of Korea VenturesPOSCO Capital

Beyond the preview

Go deeper on Ulmus Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ulmus Investment.

Explore the full profile